Clinical Trials Logo

Androgenetic Alopecia clinical trials

View clinical trials related to Androgenetic Alopecia.

Filter by:

NCT ID: NCT03694067 Completed - Clinical trials for Androgenetic Alopecia

Androgenetic Alopecia and the JAK-STAT Pathway

Start date: October 15, 2018
Phase:
Study type: Observational

It is a well known fact that the JAK-STAT pathway plays a pivotal role in the pathogenesis of alopecia areata. Both phosphorylated STAT 1 and 3 have been found to be upregulated in the disease. However, whether this pathway plays a role in other hair loss disorders remains unclear. The study aims at assessing STAT3 levels in male patients with androgenetic alopecia. The investigators hypothesize that STAT3 levels will be elevated (due to a previous study proving that JAK-STAT pathway is involved in non-immune mediated hair loss in mice.

NCT ID: NCT03689452 Completed - Clinical trials for Androgenetic Alopecia

The Effect of Platelet Rich Plasma on Non-scarring Alopecia

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy of platelet rich plasma (PRP) injections for non-scaring alopecia in women. A randomized, placebo-controlled clinical trial will be performed where patients with non-scarring alopecia will either receive injections of their own PRP or injections of normal saline (placebo). Patients in the treatment group (Group A) will have a small amount of their own blood drawn and have their PRP injected into their scalp four times. The injections will be given at weeks zero, four, eight, and twenty four. The placebo group (Group B) will be given the same schedule but will receive sham injections only and will not have any blood drawn. Both groups will have clinical data collected at all visits, including a screening visit before enrollment and a final assessment visit at week 40, for a total of 6 study visits per patient. Data collection will include representative photographs of the scalp and measurements of hair thickness. The results from the two groups will then be compared. In summary, all study participants will have a screening visit before enrollment, four study visits for sub-dermal scalp injections, and one final assessment visit at week 40.

NCT ID: NCT03495817 Completed - Clinical trials for Androgenetic Alopecia

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Start date: March 22, 2018
Phase: Phase 2
Study type: Interventional

Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.

NCT ID: NCT03394235 Completed - Clinical trials for Androgenetic Alopecia

Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter

Start date: February 2, 2018
Phase: N/A
Study type: Interventional

This study evaluates the optimizing parameters of long pulse Nd:YAG Laser for reducing the size of hair shaft diameter of the donor for hair transplantation. All participants will receive long-pulsed Nd-YAG laser treatments with three different parameters at the occipital area.

NCT ID: NCT03376581 Completed - Clinical trials for Androgenetic Alopecia

The Utility of Platelet Rich Plasma in Hair Loss

Start date: November 28, 2017
Phase: Early Phase 1
Study type: Interventional

Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation. The purpose of this research is to investigate the potential of PRP injection for treatment of hair loss. Clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical Doppler tomography and multispectral imaging.

NCT ID: NCT02848300 Completed - Clinical trials for Androgenetic Alopecia

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).

NCT ID: NCT02791243 Completed - Clinical trials for Androgenetic Alopecia

Photosensitization Study in Androgenetic Alopecia

Start date: May 9, 2016
Phase: Phase 1
Study type: Interventional

This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)

NCT ID: NCT02729415 Completed - Clinical trials for Androgenetic Alopecia

Point-of-Care Adipose-derived Cells for Hair Growth

ASVF-2016
Start date: October 2016
Phase: N/A
Study type: Interventional

Androgenetic alopecia (AGA) is the most common form of hair loss and affects 50% and 23% of Caucasian men and women, respectively, over the age of 50. The percentage of men and women affected over the age of 70 increases to 80% and 60% of Caucasian men and women, respectively. Although alopecia is considered a minor dermatologic condition, it is seen as a serious condition with major life consequences by those with alopecia and has been associated with increased incidence of myocardial infarction, hypertension and hypercholesterolaemia. Androgenetic alopecia is associated with feelings of anxiety, depression and various personality disorders among men and women due to physical appearance. Depression, anxiety, aggressiveness, impaired quality of life and social inadequacy have been documented. The presence of alopecia in women is particularly stressful. ADSCs (Adipose Derived Stromal Cells), also called Stromal Vascular Fraction (SVF) cells, include regenerative cell populations derived from adipose tissue and thus are potentially important to multiple disease processes and therapeutic applications for the repair and regeneration of acute and chronically damaged tissues. It has been postulated that SVF cells may promote hair regeneration by increasing the hair-inducing ability of dermal papillae (DP) cells. The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF cells for the treatment of alopecia.

NCT ID: NCT02626780 Completed - Clinical trials for Androgenetic Alopecia

Adipose-derived SVF for Treatment of Alopecia

Start date: July 20, 2016
Phase: N/A
Study type: Interventional

The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF for the treatment of alopecia.

NCT ID: NCT02591355 Completed - Clinical trials for Androgenetic Alopecia

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

Start date: September 6, 2017
Phase: N/A
Study type: Interventional

Platelet rich plasma (PRP) therapy is a novel therapeutic modality that has seen broad applications for a number of medical indications including those in orthopedics, dentistry, and dermatology. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss, but to the best of our knowledge, there has been only one published case series documenting its use for this indication.